CTLT241220P65000
- 0.00
- 0.000.00%
Catalent Newsroom
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
Catalent Gains Amid Report Buyer Working on Contact Extensions With Drugmakers
Catalent Stock Soars to 52-Week High, Hits $61.55
Tuesday S&P 500 Pulls Back From Highs, Nasdaq Climbs | Live Stock
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
December Starts With a Mixed Market | Live Stock
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
CDMO Market Opportunities and Competitive Landscape Report 2024, With Profiles of Thermo Fisher Scientific, Merck, Lonza, Catalent and WuXi AppTec
Wednesday Ends With Index Decline | Wall Street Today
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
European Equities Close Lower in Tuesday Trading
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
S&P 500, Dow Hit Records Right After Open | Live Stock
Market Chatter: Novo Holdings to Win EU Approval for $16.5 Billion Catalent Takeover
The EU may unconditionally approve novo-nordisk a/s's acquisition of catalent.
The European Commission may unconditionally approve novo-nordisk a/s's parent company, Novo Holdings, to acquire the usa contract pharmaceutical company catalent for 16.5 billion USD.
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
EU Antitrust Regulators Expected to Approve Novo Holdings' $16.5B Acquisition of Catalent Without Conditions